Subcutaneous Progesterone Versus Vaginal Progesterone for Endometrial Preparation in Fresh Donated Oocytes Recipients

Launched by INSTITUTO BERNABEU · Feb 12, 2015

Keywords

ClinConnect Summary

Exploratory study with a control group treated according to our Service's usual therapeutic regimen for the transfer of embryos with donor oocytes.

The controlled ovarian stimulation protocol in oocyte donors is always calculated according to the standard protocol at the Bernabeu Institute. Endometrial preparation will be carried out following the standard protocol of the Bernabeu Institute as follows: the oestrogen will be administered transdermally and patients with maintained ovarian function undergo medical hypophysectomy with depot GnRH agonists administered in the mid-luteal phase of...

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Female, aged from 18 to 49 years (both inclusive)
• • Woman who wishes to become pregnant
• • Endometrial thickness greater 7 mm on the day of patient randomisation to one of the progesterone groups
• • Six or more donor retrieved oocytes
• • Patient programmed for fresh embryo transfer on day +5 of embryo culture
• • BMI lower than 30 Kg/m2
• • Infertility that justifies treatment with donor oocytes
• • Male with no known karyotype alterations
• • Semen by ejaculation from either the partner or from a bank
• • Uterus able to support embryo implantation and pregnancy
• • Absence of pregnancy before starting the embryo transfer cycle
• • Has given prior written consent
• Exclusion Criteria:
• • - Important systemic diseases, endocrine-metabolic abnormalities involving the pituitary, thyroid, adrenals, pancreas, liver or kidney.
• • HIV, HBV or HCV seropositivity
• • Undiagnosed vaginal bleeding
• • Pregnancy, breastfeeding or any contraindication to becoming pregnant
• • Malformation of sexual organs incompatible with pregnancy
• • Known allergy to progesterone preparations or their excipients
• • Current dependence on alcohol, drugs or psychotropic medication
• • Concurrent participation in another study
• • Concomitant medication that could interfere with the study medication: different hormonal treatments used in the study, except thyroid hormones, antipsychotics, anxiolytics, hypnotics, sedatives, chronic treatment with prostaglandin inhibitors